PT - JOURNAL ARTICLE AU - Kevin W. McConeghy AU - Barbara Bardenheier AU - Andrew W. Huang AU - Elizabeth M. White AU - Richard A. Feifer AU - Carolyn Blackman AU - Christopher M. Santostefano AU - Yoojin Lee AU - Frank DeVone AU - Christopher W. Halladay AU - James L. Rudolph AU - Andrew R. Zullo AU - Vincent Mor AU - Stefan Gravenstein TI - Effectiveness of a SARS-CoV-2 mRNA vaccine booster dose for prevention of infection, hospitalization or death in two nation-wide nursing home systems AID - 10.1101/2022.01.25.22269843 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.25.22269843 4099 - http://medrxiv.org/content/early/2022/01/28/2022.01.25.22269843.short 4100 - http://medrxiv.org/content/early/2022/01/28/2022.01.25.22269843.full AB - Background A SARS-CoV-2 vaccine booster dose has been recommended for all nursing home residents. However, we lack effectiveness data on boosters preventing infection, death and hospitalization in this frail population.Methods We emulated nested target trials in two large nursing home systems in parallel to evaluate the effectiveness of a SARS-CoV-2 mRNA vaccine booster at preventing infection, hospitalization, or death. Residents who completed a 2-dose series of the mRNA vaccine and were eligible for a booster were included in from September 22, 2021 to November 5, 2021. Outcomes were measured through December 18, 2021, including test-confirmed SARS-CoV-2 infection, hospitalization, or death. The vaccine effectiveness at day 42 was estimated with a Kaplan-Meier estimator, both unadjusted and weighted with the inverse probability of treatment.Results The two NH systems were large and multi-state, System 1 included 200 NH (8,538 control and 5,721 boosted residents) and System 2 included 127 NHs (4,100 control and 2,291 boosted residents). Booster vaccination reduced infections by 50.4% (95% Confidence Interval [CI]: 29.4%, 64.7%) SARS-CoV-2 infections in System 1 and 58.2% (32.3%, 77.8%) in System 2. Boosted residents in System 1 also had a 97.3% (86.9%, 100.0%) reduction in SARS-CoV-2 associated death, but too few events for comparison in System 2.Conclusions During a Delta predominant period, SARS-CoV-2 booster vaccination significantly reduced infection in two U.S. nursing home systems. In the larger System 1 a 97% reduction in SARS-CoV-2 related death was also observed. These findings strongly support administration of vaccine boosters to nursing home residents.Competing Interest StatementKWM, BB, SG and ARZ have received investigator-initiated to their institutions from Sanofi-Pasteur, Seqirus and Pfizer for other non-COVID-19 vaccine-related work. VM serves as Chair of the Scientific Advisory Committee at NaviHealth, Inc, was former Chair of the Independent Quality Committee at HCR ManorCare, and is the former Director of PointRight Inc, where he holds less than 1% equity; and received personal fees from NaviHealth outside the submitted work. The remaining authors declare that they have no relevant financial interests. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Funding StatementThis work was supported by the National Institute on Aging (3P01AG027296-11S1, PI: Vincent Mor and 3U54AG063546-02S2, PI: Vincent Mor & Sarah Berry). Dr. Zullo was also supported by grants R01AG045441, RF1AG061221, R01AG065722, and R21AG061632 from the National Institute on Aging (NIA) and by grant U54GM1156775 from the National Institute of General Medical Sciences (NIGMS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Brown University institutional review board (IRB) and the VA data was approved by the Providence VA Medical Center IRBI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data presented in this study contains protected health information and cannot be shared in its person-level form. However the authors can commit to responding to reasonable inquires about the data and sharing summary-level information when requested.